Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparison of Botulinum Toxin A Injection Patterns in Blepharospasm
NCT02327728Unknown
- Sponsor
- YangHui Biotech
- Start
- Feb 2013
- Primary completion
- Dec 2015
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, double-blind trial of botulinum toxin type A in benign essential blepharospasm (BEB) (2 arms), sponsored by YangHui Biotech. Primary endpoints: Jankovic Rating Scale at 3 months and Tear Meniscus Height at 3 months. Status: unknown.
02
Drugs
botulinum toxin type A
03
Conditions
benign essential blepharospasm (BEB)
Beyond the preview
Go deeper on NCT02327728.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02327728.